62 Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis* 2014;73:132–7.

63 McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. *N Engl J Med* 2021;384:1227–39.

64 Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. *RMD Open* 2023;9:e002735.

65 Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. *Ann Rheum Dis* 2020;79:1400–13.

66 Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance. *Ann Rheum Dis* 2023;82:901–10. 10.1136/ard-2022-223715 Available: http://dx.doi.org/10.1136/ard-2022-223715

67 Mease P, Gladman D, Coates L, et al. 16-week results from FOREMOST, a placebo-controlled study involving oligoarticular psoriatic arthritis treated with apremilast. *Arthritis Rheumatol* 2023;75.

68 Schett G, Lories RJ, D'Agostino M-A, et al. Enthesitis: from pathophysiology to treatment. *Nat Rev Rheumatol* 2017;13:731–41.

69 Marchesoni A, De Marco G, Merashli M, et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. *Rheumatology* 2018;57:32–40.

70 Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. *Ann Rheum Dis* 2021;80:582–90.

71 Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in Tnf naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. *RMD Open* 2020;6:e001149.

72 Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. *Arthritis Rheumatol* 2019;71:258–70.

73 Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. *The Lancet Rheumatology* 2021;3:e715–23.

74 Ogdie A, Shin DB, Love TJ, et al. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. *Rheumatology (Oxford)* 2022;61:1877–84.

75 Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. *Lancet* 2015;386:552–61.

76 Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. *N Engl J Med* 2017;376:1551–60.

77 Gottlieb AB, Merola JF, Reich K, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis:

results from EXCEED, a randomized, double-blind head-to-head monotherapy study. *Br J Dermatol* 2021;185:1124–34.

78 Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of Ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. *Br J Dermatol* 2021;184:1047–58.

79 Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *Journal of the American Academy of Dermatology* 2019;80:1029–72.

80 Pittam B, Gupta S, Harrison NL, et al. Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. *Rheumatology* 2020;59:2199–206.

81 Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2016;375:1946–60.

82 Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2017;376:1723–36.

83 Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2019;381:1201–14.

84 Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. *Lancet* 2022;399:2113–28.

85 Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2023;388:1966–80.

86 Letarouilly J-G, Pham T, Pierache A, et al. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study. *Rheumatology* 2022;61:2848–55.

87 Emond B, Ellis LA, Chakravarty SD, et al. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with Interleukin-17A or phosphodiesterase 4 inhibitors. *Curr Med Res Opin* 2019;35:1751–9.

88 Yamada A, Wang J, Komaki Y, et al. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-Interleukin-17 agents. *Aliment Pharmacol Ther* 2019;50:373–85.

89 Ye W, Tucker LJ, Coates LC. Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. *Drugs* 2018;78:1705–15.

90 Coates LC, Pillai SG, Tahir H, et al. Withdrawing Ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study. *Arthritis Rheumatol* 2021;73:1663–72.

91 Ruwaard J, L'Ami MJ, Kneepkens EL, et al. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. *Scandinavian Journal of Rheumatology* 2023;52:129–36.

92 Nash P, Mease PJ, Fleishaker D, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance. *Lancet Rheumatol* 2021;3:e28–39.

93 Tarannum S, Widdifield J, Wu CF, et al. Understanding sex-related differences in Healthcare utilisation among patients with inflammatory arthritis: a population-based study. *Ann Rheum Dis* 2023;82:283–91.